Analysts reviewing sector P/E comparisons see PFE as undervalued, supporting a strong buy recommendation in near-term PFE stock price forecasts. While the stock has risen 15% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us. The bottom line is that if PFE were to trade at its historical mean P/E multiple or dividend yield the stock is deeply undervalued. Pfizer's dividend yield near 6% remains attractive for income-focused portfolios, adding a stable component to the bullish PFE stock price forecast in the current rate environment.